David J. Pasta

David J. Pasta

Auto-generated profile, based on publicly available information

David J. Pasta

ICON Clinical Research, San Francisco, California; and

Research Focus & Metrics

Academic Career Length

42Years (1985-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2005 in Journal of Urology
Verified
Journal Article
Closed access
MCMatthew R. Cooperberg
Matthew R. Cooperberg
DPDavid J. Pasta
David J. Pasta
EEEric P. Elkin
Eric P. Elkin
MLMark S. Litwin
Mark S. Litwin
DLDavid M. Latini
David M. Latini
PCPeter R. Carroll
Peter R. Carroll
Purpose: Multivariate prognostic instruments aim to predict risk of recurrence among patients with localized prostate cancer. We devised a novel risk assessment tool which would be a strong...

27 July 2005 in JAMA
Verified
Journal Article
Open access
PDF file
ABAnvar Babaev
Anvar Babaev
PFPaul D. Frederick
Paul D. Frederick
DPDavid J. Pasta
David J. Pasta
NENathan Every
Nathan Every
TSTina Sichrovsky
Tina Sichrovsky
FIfor the NRMI Investigators
for the NRMI Investigators
Cardiogenic shock remains the leading cause of death in patients hospitalized with acute myocardial infarction (AMI).1 The SHOCK randomized trial2,3 demonstrated that in patients with AMI complicated by cardiogenic shock, early mechanical revascularization reduced 6- and 12-month mortality compared with initial medical stabilization (including intra-aortic balloon pump [IABP] counterpulsation and fibrinolytic therapy) followed by late or no revascularization. There was a significant interaction between treatment and age, with apparent lack of benefit of early revascularization for the small subset of patients aged 75 years or older.2,3 Based on these findings, the American College of Cardiology (ACC) and the American Heart Association (AHA) elevated early mechanical revascularization for cardiogenic shock to a class I recommendation for patients younger than 75 years with ST-elevation left bundle-branch block AMI in their revised guidelines for the management of AMI published in September 1999.4

1 October 2010 in Fertility and Sterility
Verified
Journal Article
Closed access
GAG. David Adamson
G. David Adamson
DPDavid J. Pasta
David J. Pasta

1 August 2007 in The Journal of Pediatrics
Verified
Journal Article
Closed access
MKMichael W. Konstan
Michael W. Konstan
WMWayne J. Morgan
Wayne J. Morgan
SBSteven M. Butler
Steven M. Butler
DPDavid J. Pasta
David J. Pasta
MCMarcia L. Craib
Marcia L. Craib
CJCharles A. Johnson
Charles A. Johnson

1 September 1999 in Urology
Verified
Journal Article
Closed access
MLMark S Litwin
Mark S Litwin
SFScott C Flanders
Scott C Flanders
DPDavid J Pasta
David J Pasta
MSMarcia L Stoddard
Marcia L Stoddard
DLDeborah P Lubeck
Deborah P Lubeck
JHJames M Henning
James M Henning

27 April 2007 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
EYEdward Yelin
Edward Yelin
LMLouise Murphy
Louise Murphy
MCMiriam G. Cisternas
Miriam G. Cisternas
AFAimee J. Foreman
Aimee J. Foreman
DPDavid J. Pasta
David J. Pasta
CHCharles G. Helmick
Charles G. Helmick
Objective: To obtain estimates of medical care expenditures and earnings losses associated with arthritis and other rheumatic conditions and the increment in such costs attributable to arthritis and other rheumatic conditions in the US in 2003, and to compare these estimates with those from 1997.Methods: Estimates for 2003 were derived from the Medical Expenditures Panel Survey (MEPS), a national probability sample of households. We tabulated medical care expenditures of adult MEPS respondents, stratified by arthritis and comorbidity status, and used regression techniques to estimate the increment of medical care expenditures attributable to arthritis and other rheumatic conditions. We also estimated the earnings losses sustained by working‐age adults with arthritis and other rheumatic conditions. Estimates for 2003 were compared with those from 1997, inflated to 2003 terms.Results: In 2003, there were 46.1 million adults with arthritis and other rheumatic conditions (versus 36.8 million in 1997). Adults with arthritis and other rheumatic conditions incurred mean medical care expenditures of $6,978 in 2003 (versus $6,346 in 1997), of which $1,635 was for prescriptions ($899 in 1997). Expenditures for adults with arthritis and other rheumatic conditions totaled $321.8 billion in 2003 ($233.5 billion in 1997). In 2003, the mean increment in medical care expenditures attributable to arthritis and other rheumatic conditions was $1,752 ($1,762 in 1997), for a total of $80.8 billion ($64.8 billion in 1997). Persons with arthritis and other rheumatic conditions ages 18–64 years earned $3,613 less than other persons (versus $4,551 in 1997), for a total of $108.0 billion (versus $99.0 billion). Of this amount, $1,590 was attributable to arthritis and other rheumatic conditions (versus $1,946 in 1997), for a total of $47.0 billion ($43.3 billion in 1997).Conclusion: Our findings indicate that the increase in medical care expenditures and earnings losses between 1997 and 2003 is due more to an increase in the number of persons with arthritis and other rheumatic conditions than to costs per case.